The FDA just dropped a final guidance entitled "Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of a Drug" that will be of interest to the immunogenicity and pharmacokinetics community, as well as those responsible for compiling the data sets for filings.
The Introduction describes the rationale and content of the guidance:
"This guidance is intended to assist industry in the submission of datasets from clinical studies that evaluate immunogenicity and its impact on the pharmacokinetics of a drug. In this document, FDA provides detailed information and specifications for these datasets. These specifications may elicit discussions between the sponsor2 and reviewers regarding issues with trial design or conduct that may affect the content of the analysis datasets. These specifications were built to support the data standards and processes described in the technical specification document Study Data Technical Conformance Guide (March 2026)."
The guidance "provides detailed data specifications for the following datasets:
• Analysis Dataset for Immunogenicity Specimen (ADIS)
• Analysis Dataset for Pharmacokinetic Concentrations (ADPC)
• Subject-Level Analysis Dataset (ADSL)"
As with all new guidance, it will take a thorough read to get all the details extracted and implemented; especially on upcoming filings.
#IMG #PK #DataSetStandard
Guidance for Industry
| U.S. Food and Drug Administration |
remove preview |
|
|
------------------------------
Mark Arnold Ph.D., FAAPS
Westampton, NJ
[email protected]Bioanalytical Solution Integration
LinkedIn:
https://www.linkedin.com/in/markearnoldphd/Website & Blog: Bioanalysis & Biomarkers <bioanalysisandbiomarkers.blogspot.com>
------------------------------
</bioanalysisandbiomarkers.blogspot.com>